Pharma

Pharmalot

Lilly lowers most insulin costs to $35 a month in response to Covid-19

By Ed Silverman

Pharma

Pharmalittle: India to allow limited exports of malaria drug; some Trump allies profit if hydroxychloroquine is approved

By Ed Silverman

Pharmalot

Former Novartis exec wants to repurpose generic drugs to fight Covid-19

By Ed Silverman

Health

A $30 billion gamble: Pandemic expert calls for making Covid-19 vaccines before we know they work

By Helen Branswell

Pharmalot

WHO director-general endorses a voluntary intellectual property pool to develop Covid-19 products

By Ed Silverman

Pharmalot

Pharmalittle: States try to prevent hoarding of drug used for Covid-19; is BARDA ready for the coronavirus?

By Ed Silverman

Pharmalot

Gilead ramps up production of experimental Covid-19 treatment amid criticism over access

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Sanofi poised to supply millions of doses of malaria drug; Roche unit apologizes for ‘Wuhan’ virus label

By Ed Silverman

Pharmalot

Large employers could have saved money if more biosimilars had been prescribed

By Ed Silverman

Pharmalot

Pharmalittle: Novartis scraps generic sale to Aurobindo; another small study suggests old malaria drug works

By Ed Silverman

Pharmalot

The FDA warns Pfizer over yet another former Hospira manufacturing plant

By Ed Silverman

Pharmalot

FDA asks manufacturers to recall heartburn drugs over traces of a possible carcinogen

By Ed Silverman

Pharmalot

Pharmalittle: U.S. asks India to list restrictions on pharma ingredients; Giuliani wants FDA to fast-track a drug for Covid-19

By Ed Silverman

Pharmalot

Pharmalittle: A TB vaccine is tested against the coronavirus; FDA doesn’t punish Novartis over data integrity scandal

By Ed Silverman

Pharmalot

FDA closes review of Novartis data integrity scandal without punishing the drug maker

By Ed Silverman

The Pharmalot View

We shouldn’t rush to use an unproven malaria drug to treat the coronavirus

By Ed Silverman

In the Lab

‘It’s the disparity in who gets affected’: A sickle cell doctor tracks dollars and drug development

By Elizabeth Cooney

Pharmalot

Pharmalittle: Drug pricing legislation is on the back burner; FDA issues emergency use for old malaria drugs

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Conservative group pushes for malaria drug approval for Covid-19; OTC drug industry to get an overhaul

By Ed Silverman

Pharmalot

DEA proposes new rule to approve new suppliers of marijuana for research

By Ed Silverman

Pharmalot

Pharmalittle: Gilead asks FDA to rescind orphan status for Covid-19 drug; Bristol delays MS drug launch due to coronavirus

By Ed Silverman

Pharma

Bristol’s MS drug approval is good news for shareholders but patients will have to wait

By Adam Feuerstein

Pharmalot

The tables are turned: Chinese regulator scolds a U.S. company for drug-manufacturing problems

By Ed Silverman

Pharmalittle: More clinical trials derailed by Covid-19; Pfizer jumpstarts tests on a drug to fight the pandemic

Pfizer says coronavirus drug could enter testing by fall

Opioid-overdose prescriptions may go unfilled due to the cost

Pharmalittle: WIPO holds talks to widen access to Covid-19 medical products; DEA moves to ease Covid-19 drug shortages

Lilly lowers most insulin costs to $35 a month in response to Covid-19

Pharmalittle: India to allow limited exports of malaria drug; some Trump allies profit if hydroxychloroquine is approved

Former Novartis exec wants to repurpose generic drugs to fight Covid-19

A $30 billion gamble: Pandemic expert calls for making Covid-19 vaccines before we know they work

WHO director-general endorses a voluntary intellectual property pool to develop Covid-19 products

Pharmalittle: States try to prevent hoarding of drug used for Covid-19; is BARDA ready for the coronavirus?

Gilead ramps up production of experimental Covid-19 treatment amid criticism over access

Up and down the ladder: The latest comings and goings

Pharmalittle: Sanofi poised to supply millions of doses of malaria drug; Roche unit apologizes for ‘Wuhan’ virus label

Large employers could have saved money if more biosimilars had been prescribed

Pharmalittle: Novartis scraps generic sale to Aurobindo; another small study suggests old malaria drug works

The FDA warns Pfizer over yet another former Hospira manufacturing plant

FDA asks manufacturers to recall heartburn drugs over traces of a possible carcinogen

Pharmalittle: U.S. asks India to list restrictions on pharma ingredients; Giuliani wants FDA to fast-track a drug for Covid-19

Pharmalittle: A TB vaccine is tested against the coronavirus; FDA doesn’t punish Novartis over data integrity scandal

FDA closes review of Novartis data integrity scandal without punishing the drug maker

We shouldn’t rush to use an unproven malaria drug to treat the coronavirus

‘It’s the disparity in who gets affected’: A sickle cell doctor tracks dollars and drug development

Pharmalittle: Drug pricing legislation is on the back burner; FDA issues emergency use for old malaria drugs

Up and down the ladder: The latest comings and goings

Pharmalittle: Conservative group pushes for malaria drug approval for Covid-19; OTC drug industry to get an overhaul

DEA proposes new rule to approve new suppliers of marijuana for research

Pharmalittle: Gilead asks FDA to rescind orphan status for Covid-19 drug; Bristol delays MS drug launch due to coronavirus

Bristol’s MS drug approval is good news for shareholders but patients will have to wait

The tables are turned: Chinese regulator scolds a U.S. company for drug-manufacturing problems